



Indoco Remedies gains final ANDA approval for Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg and 20 mg

Rivaroxaban Tablets USP will be manufactured at the company's facility located in Goa

By EP News Bureau On Aug 13, 2025



Indoco Remedies announced final approval of the Company's Abbreviated New Drug Application (ANDA) for Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg and 20 mg, to market a generic equivalent to the reference listed drug (RLD), Xarelto Tablets, 2.5 mg, 10 mg, 15 mg and 20 mg, of Janssen Pharmaceuticals, from USFDA.

Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg and 20 mg are bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xarelto Tablets, 2.5 mg, 10 mg, 15 mg and 20 mg, of Janssen Pharmaceuticals.

Rivaroxaban Tablets USP, will be manufactured by Indoco Remedies, at their manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa, India.

Rivaroxaban is used for the treatment of venous thromboembolism (VTE).